Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene (NGNE – Research Report) today and set a price target of $46.00. The ...
U.S. News & World Report1y
Stifel, Nicolaus & Co Incorporated
What should I know about this firm? Stifel, Nicolaus & Co. Inc. offers investment advising services that let individuals choose the level of control they have over their portfolio. Everyday ...
Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alkermes (ALKS – Research Report) today and set a price target of $36.00. The ...